Acorai

Heart Failure is $300bn burden, affecting over 60 million patients globally. ICPM has been demonstrated as the most efficient way to manage Heart Failure patients. The problem is that current ICPM solutions are invasive and costly, rendering the adoption rate to below 5%. Acorai has developed a first-of-its-kind medical device for non-invasive and scalable ICPM. Acorai has demonstrated equivalence to invasive ICPM solutions, and can hence enable cost-efficient Heart Failure at scale.